November 14, 2025

SABR May Be Comparable to Surgery for Early-Stage NSCLC

Stereotactic ablative radiation therapy (SABR) was found to be noninferior to surgical resection in terms of overall survival for patients with early-stage non–small cell lung cancer (NSCLC), accordin...

The ASCO Post

November 04, 2025

ADA standards on CBCT systems, DICOM available for comment

The draft standards are available for review and comment until Dec. 5.

ADA News

November 04, 2025

$16 Million PRISM Trial Will Explore AI in Breast Cancer Screening

The newly funded, multi-institutional PRISM clinical trial will evaluate whether AI can help support radiologists in interpreting mammograms more accurately, with the goal of improving breast cancer s...

The ASCO Post

October 29, 2025

Hybrid AI Approach With Uncertainty Quantification for Mammography Reading Supports Safe Workload Reduction

Investigators have developed and tested a hybrid reading strategy for screening mammography images with artificial intelligence (AI) that includes reads from radiologists and a stand-alone AI interpre...

The ASCO Post

October 22, 2025

Biomarker-Driven Apalutamide Therapy for Patients With Recurrent Prostate Cancer

Use of PAM50 subtyping allowed clinicians to determine which patients with recurrent prostate cancer were most likely to benefit from the addition of apalutamide hormonal therapy to salvage radiothera...

The ASCO Post

October 14, 2025

Breast Screening: The Age Question

Screening every two years offers greater life-year gains in breast cancer care.

Conexiant

October 08, 2025

Breast Cancer Research: Updates for 2025

Novel treatment protocols are demonstrating significant improvements in overall survival and progression-free survival for breast cancer patients while targeted therapies continue to expand treatment options

Baptist Health South Florida

October 07, 2025

Newer Radiation Technique Reduces Side Effects While Maintaining Effectiveness

Researchers at Fox Chase Cancer Center have demonstrated that pulsed low dose rate (PLDR) chemoradiation therapy can significantly reduce side effects while maintaining treatment effectiveness for patients with esophageal cancer and non-small cell lung cancer.

Fox Chase Cancer Center

September 29, 2025

Addition of Xevinapant to Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck

In a phase III trial (TrilynX) reported in the Journal of Clinical Oncology, Bourhis et al found that the addition of xevinapant (an inhibitor of apoptosis proteins inhibitor) to platinum-based chemor...

The ASCO Post